These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

790 related items for PubMed ID: 23508784

  • 21. Prevalence and Phenotypic Expression of Mutations in the MYH7, MYBPC3 and TNNT2 Genes in Families with Hypertrophic Cardiomyopathy in the South of Brazil: A Cross-Sectional Study.
    Mattos BP, Scolari FL, Torres MA, Simon L, Freitas VC, Giugliani R, Matte Ú.
    Arq Bras Cardiol; 2016 Sep; 107(3):257-265. PubMed ID: 27737317
    [Abstract] [Full Text] [Related]

  • 22. Genetic diagnosis of hypertrophic cardiomyopathy using mass spectrometry DNA arrays and high resolution melting.
    Santos S, Lança V, Oliveira H, Branco P, Silveira L, Marques V, Brito D, Madeira H, Bicho M, Fernandes AR.
    Rev Port Cardiol; 2011 Jan; 30(1):7-18. PubMed ID: 21425739
    [Abstract] [Full Text] [Related]

  • 23. Presence of Hypertrophic Cardiomyopathy Related Gene Mutations and Clinical Manifestations in Vietnamese Patients With Hypertrophic Cardiomyopathy.
    Tran Vu MT, Nguyen TV, Huynh NV, Nguyen Thai HT, Pham Nguyen V, Ho Huynh TD.
    Circ J; 2019 Aug 23; 83(9):1908-1916. PubMed ID: 31308319
    [Abstract] [Full Text] [Related]

  • 24. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H, Yang H, Rhee JW, Zhang JZ, Lam CK, Sallam K, Chang ACY, Ma N, Lee J, Zhang H, Blau HM, Bers DM, Wu JC.
    Eur Heart J; 2019 Dec 01; 40(45):3685-3695. PubMed ID: 31219556
    [Abstract] [Full Text] [Related]

  • 25. Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.
    Ferrantini C, Coppini R, Pioner JM, Gentile F, Tosi B, Mazzoni L, Scellini B, Piroddi N, Laurino A, Santini L, Spinelli V, Sacconi L, De Tombe P, Moore R, Tardiff J, Mugelli A, Olivotto I, Cerbai E, Tesi C, Poggesi C.
    J Am Heart Assoc; 2017 Jul 22; 6(7):. PubMed ID: 28735292
    [Abstract] [Full Text] [Related]

  • 26. Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.
    Alves ML, Dias FAL, Gaffin RD, Simon JN, Montminy EM, Biesiadecki BJ, Hinken AC, Warren CM, Utter MS, Davis RT, Sakthivel S, Robbins J, Wieczorek DF, Solaro RJ, Wolska BM.
    Circ Cardiovasc Genet; 2014 Apr 22; 7(2):132-143. PubMed ID: 24585742
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy.
    Revera M, van der Merwe L, Heradien M, Goosen A, Corfield VA, Brink PA, Moolman-Smook JC.
    Cardiovasc Res; 2008 Mar 01; 77(4):687-94. PubMed ID: 18029407
    [Abstract] [Full Text] [Related]

  • 30. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.
    Mori AA, Castro LR, Bortolin RH, Bastos GM, Oliveira VF, Ferreira GM, Hirata TDC, Fajardo CM, Sampaio MF, Moreira DAR, Pachón-Mateos JC, Correia EB, Sousa AGMR, Brión M, Carracedo A, Hirata RDC, Hirata MH.
    Forensic Sci Int Genet; 2021 May 01; 52():102478. PubMed ID: 33588347
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Spectrum of Mutations in Hypertrophic Cardiomyopathy Genes Among Tunisian Patients.
    Jaafar N, Gómez J, Kammoun I, Zairi I, Amara WB, Kachboura S, Kraiem S, Hammami M, Iglesias S, Alonso B, Coto E.
    Genet Test Mol Biomarkers; 2016 Nov 01; 20(11):674-679. PubMed ID: 27574918
    [Abstract] [Full Text] [Related]

  • 34. Dilated cardiomyopathy mutations in thin-filament regulatory proteins reduce contractility, suppress systolic Ca2+, and activate NFAT and Akt signaling.
    Robinson P, Sparrow AJ, Patel S, Malinowska M, Reilly SN, Zhang YH, Casadei B, Watkins H, Redwood C.
    Am J Physiol Heart Circ Physiol; 2020 Aug 01; 319(2):H306-H319. PubMed ID: 32618513
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
    Ramachandra CJA, Kp MMJ, Chua J, Hernandez-Resendiz S, Liehn EA, Knöll R, Gan LM, Michaëlsson E, Jonsson MKB, Ryden-Markinhuhta K, Bhat RV, Fritsche-Danielson R, Lin YH, Sadayappan S, Tang HC, Wong P, Shim W, Hausenloy DJ.
    Cardiovasc Res; 2022 Jan 29; 118(2):517-530. PubMed ID: 33705529
    [Abstract] [Full Text] [Related]

  • 38. Familial hypertrophic cardiomyopathy: functional effects of myosin mutation R723G in cardiomyocytes.
    Kraft T, Witjas-Paalberends ER, Boontje NM, Tripathi S, Brandis A, Montag J, Hodgkinson JL, Francino A, Navarro-Lopez F, Brenner B, Stienen GJ, van der Velden J.
    J Mol Cell Cardiol; 2013 Apr 29; 57():13-22. PubMed ID: 23318932
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.